Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:31:45.247Z.
Calculation as of: 2026-10-06T15:31:45.247Z.
Quote observation: 2026-10-06T15:30:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6dae1ed753b385efcb651dd8f32a10b6f9886011747f410ddce9f57bee9a14c9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$4.91B
EBITDA Yield
N/A
TTM Avg
0.05%
3Y Avg
0.05%
5Y Avg
0.05%
Market Cap
$4.68B
EBITDA Yield
2.86%
TTM Avg
2.61%
3Y Avg
2.07%
5Y Avg
1.96%
Market Cap
$5.08B
EBITDA Yield
6.19%
TTM Avg
6.37%
3Y Avg
5.19%
5Y Avg
4.76%
Market Cap
$4.65B
EBITDA Yield
7.16%
TTM Avg
7.73%
3Y Avg
6.77%
5Y Avg
5.88%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dianthus Therapeutics, Inc. (DNTH) | $4.91B | N/A | N/A | N/A | N/A |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.89B | N/A | N/A | N/A | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.91B | N/A | 0.05% | 0.05% | 0.05% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.75B | N/A | N/A | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 2.86% | 2.61% | 2.07% | 1.96% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.08B | 6.19% | 6.37% | 5.19% | 4.76% |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 7.16% | 7.73% | 6.77% | 5.88% |
| Erasca, Inc. (ERAS)vs › | $5.15B | N/A | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.62B | 1.32% | 0.79% | 0.79% | 0.79% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.23B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
